Market Newsdesk

What you need to know:

• Enterprises will be able to deploy a dedicated, private edge compute platform fully integrated with AWS cloud services and Verizon 5G private networks to improve productivity, safety and operational efficiencies
• Factories, warehouses, school campuses and large businesses will be able to use Verizon Private Edge services on-premises to support low-latency use cases like autonomous mobile robots and hazard condition monitoring
• Corning will use Verizon 5G Edge with AWS Outposts to explore powering self-guided vehicles and enhance innovation at one of the world’s largest fiber-optic cable plants

BASKING RIDGE, N.J., April 05, 2021 (GLOBE NEWSWIRE) — Verizon Business and Amazon Web Services (AWS) will be expanding their 5G collaboration to deliver private mobile edge computing (MEC) to enterprise customers in the U.S who want a completely dedicated edge compute infrastructure on-premise that enables ultra-low latency, higher levels of security and deeper customization. The solution will fully integrate Verizon’s Private 5G networks and Private Edge platform with AWS Outposts, a fully managed service that offers the same AWS infrastructure, services, APIs, and tools to virtually any datacenter, co-location space, or on-premises facility for a truly consistent hybrid experience. Verizon enterprise customers can use private MEC to quickly deploy real-time enterprise applications like intelligent logistics, predictive maintenance, robotics, factory automation and more to lower costs and improve safety, precision and efficiency. Corning Incorporated, a leading materials science and advanced manufacturing innovator, will be the first company to leverage this private MEC solution.

MEC running on private networks creates a secure, dedicated computing platform within specific areas such as factories, warehouses, and large business campuses. The platform supports unified connectivity, compute and storage, without having the need for the customer to own extensive networking and IT infrastructure. The new, fully managed private MEC solution will support a wide range of industrial manufacturing applications, such as autonomous mobile robots (AMRs), predictive maintenance, quality assurance, and near real-time monitoring and hazard alerts. Verizon’s Private 5G Edge platform will give customers a reliable, secure, high bandwidth, low latency connection to AWS services, APIs, and tools running on AWS Outposts. Additionally, two smaller AWS Outposts — 1U and 2U form factors — will give customers options to deploy AWS on-premises in space-constrained locations.

“Verizon’s 5G is the platform for 21st century innovation and customers are looking to rapidly innovate, improve performance, and create new revenue streams,” said Tami Erwin, CEO of Verizon Business. “Developers are already creating new latency-dependent solutions that run on the Verizon/AWS public MEC service launched last year. Our private MEC offering will unlock that same potential for enterprise customers who need to maintain a secure, closed environment in factories, warehouses and other facilities.”

The Verizon and AWS edge computing collaboration began with the launch of Verizon 5G Edge with AWS Wavelength. AWS Wavelength extends AWS compute and storage services to the edge of Verizon’s public mobile network and provides seamless access to cloud services running in an AWS region. By doing so, AWS Wavelength minimizes the latency and network hops required to connect from a 5G device to an application hosted on AWS. Since August 2020, the companies have announced the general availability of 5G mobile edge computing via Wavelength Zones in 10 cities across the U.S.

“Private MEC is a natural expansion of our collaboration with Verizon,” said Dave Brown, Vice President Elastic Compute Cloud (EC2) at AWS. “Customers are already leveraging AWS Wavelength’s ability to provide ultra-low latency access to end users for use cases like video distribution, inference at the edge, AR/VR, and connected vehicles. Now, Private 5G MEC from AWS and Verizon brings ultra-low latency to dedicated, closed, on-premises environments for use cases such as autonomous mobile robots, quality assurance, and hazard alerting.”

Corning Tests Private MEC at Smart Factory

Verizon and AWS are working to integrate AWS Outposts with Verizon’s 5G private network to bring the private MEC platform to life for Corning Inc. Already, Corning is exploring the benefits of 5G and private MEC in Hickory, North Carolina, at one of the largest fiber-optic cable manufacturing facilities in the world. Corning and Verizon are working with Gestalt Robotics GmbH, a service provider for intelligent industrial automation, to run highly scalable edge-services on AWS Outposts that provide autonomous navigation and advanced environmental sensing “as a Service”. Gestalt Robotics’ solutions make use of computer vision and machine learning models to process sensor data received from autonomous mobile robots (AMRs), then send commands to the AMRs over the ultra-low latency, high-throughput 5G private network. The service can reduce the need for computing hardware and battery capacity on the AMRs and enable near real-time interaction and a closed-loop control of the vehicles delivering high-reliability production services within the factory.

“We’re living through one of the greatest communications evolutions in history – and at the center of it all are optical networks. At Corning, our vision is to accelerate the ways in which innovation improves people’s lives and brings the world closer together, which includes partnering with industry leaders such as Verizon and AWS to make the promise of 5G a reality,” said Michael A. Bell, senior vice president and general manager of Corning’s Optical Communications business. “We believe 5G will revolutionize the way people and companies interact with technology, and we’re excited to advance these developments in our own plant, where we manufacture the optical cable needed to support the networks. Now, with Verizon’s 5G network and mobile edge computing solution using AWS Outposts, we’re leveraging technologies like autonomous mobile robots to demonstrate how manufacturers can increase efficiency.” Watch this Corning video for more.

Learn more information about Verizon 5G Edge and Verizon’s 5G technology.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $128.3 billion in 2020. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at https://www.verizon.com/about/media-center. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Media contact:
Chris Ashraf
[email protected]
(201) 320-4259
@ChrisMoonPR

NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) — RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been published in Diabetologia, the official journal of the European Association for the Study of Diabetes (EASD).

Strong performance of the KidneyIntelX platform is attributed in part to its proprietary, blood-based biomarker technologies, exclusively licensed from the Joslin Diabetes Center and the Mount Sinai Health System.

Notably, KidneyIntelX was observed to be highly effective at both ends of the risk spectrum. In the study, KidneyIntelX more accurately identified and segmented patients into three risk categories (low, intermediate and high) when compared to clinical models, including the current standard of care, the KDIGO risk stratification algorithm. When guideline-recommended urine albumin to creatinine ratio testing was performed, the positive predictive value (PPV) for progressive decline in kidney function was 69% for those scored as high-risk by KidneyIntelX versus the 40% identified as highest-risk by KDIGO categorization. This is a 72% improvement compared to standard of care. In addition, only 7% of those scored as low-risk by KidneyIntelX experienced progression (i.e., negative predictive value of 93%).

“Diabetes is one of the leading causes of kidney failure in the United States. Appropriate treatment for kidney disease is a significant challenge in type 2 diabetes patients,” said Dr. Marina Basina, Clinical Professor, Medicine – Endocrinology, Gerontology, & Metabolism, Stanford Medicine and Medical Director of Inpatient Diabetes, Stanford Health Care. “Data from the KidneyIntelX risk assessment platform could significantly improve the care path for diabetes patients and delay the severe consequences of diabetic kidney disease. Identifying the risk for kidney disease complications in diabetic patients in the earlier stages of the disease is essential to improving kidney health and reducing health care costs.”

Accurate segmentation of patient groups based on risk will yield benefits from targeted clinical care plans. High-risk patients identified earlier in the disease cycle can be prioritized to receive precision medicine and optimized care management to slow or arrest progressive kidney disease, while low-risk patients can avoid unnecessary treatments, follow-up visits and anxiety. KidneyIntelX has the potential to uniquely inform health care providers, insurance payors and population health managers about the expected rate of progression and risk of failure in early-stage kidney disease patients. KidneyIntelX is expected to support optimization of care delivery, improve patient outcomes and reduce the $120 billion annual cost of kidney disease to the United States Medicare system.¹ 

“Given these additional clinical study findings, we are confident that KidneyIntelX will be adopted as part of the standard of care in assessing the risk of progressive kidney decline in individuals with early-stage diabetic kidney disease,” said Michael J. Donovan, MD, Ph.D., Chief Medical Officer, RenalytixAI. “These results published in Diabetologia further validate our rigorous scientific and clinical approach, which is focused on early detection and aggressive clinical intervention for those found to be at the highest risk.” 

The Diabetologia article entitled, “Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease,” is available at https://link.springer.com/article/10.1007/s00125-021-05444-0.

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.² Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

About KidneyIntelX

KidneyIntelX, is a first-in-class in vitro diagnostics platform, that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About RenalytixAI

RenalytixAI (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytixai.com

Sources

¹
United States Renal Data System

²
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC on October 28, 2020, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Media Contacts:

United States:
Jennifer Moritz
Zer0 to 5ive for RenalytixAI
(917) 748-4006
[email protected]

Outside of the United States:
Walbrook PR Limited
Paul McManus / Lianne Cawthorne
Tel: 020 7933 8780 or [email protected] 
Mob: 07980 541 893 / 07584 391 303

SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered into an agreement with East West Bank (“EWB”) in which EWB will provide a $7.5 million working capital line of credit.

The line of credit is secured by Journey Medical’s receivables and cash. Interest on the line is the greater of 4.25% or the Prime Rate plus 1%. The agreement expires in 36 months. Journey Medical intends to use the proceeds for general corporate purposes, including the advancement of the Company’s portfolio.

Claude Maraoui, President and Chief Executive Officer of Journey Medical, stated, “We are pleased to work with EWB to support our operating needs and future growth ambitions. With access to these funds, we will continue executing our plan to acquire additional dermatology products while continuing to commercialize our seven marketed prescription products that help treat and heal common skin conditions.”

About Journey Medical Corporation

Journey Medical Corporation (“Journey Medical”) is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets seven products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage pharmaceutical products and product candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our Securities and Exchange Commission filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contacts:

Jaclyn Jaffe and William Begien
Fortress Biotech, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:

Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact:

Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]  

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

Development of First-Generation ETB MT-3724 Has Been Discontinued, Company to Focus on Development of Next-Generation ETB Product Candidates Including Clinical Stage MT-5111, TAK-169 and MT-6402

AUSTIN, Texas, April 05, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that, following discussion with its co-development partner Takeda, MTEM will assume full rights to TAK-169 including taking control of clinical development from Takeda. In addition, MTEM announced the decision to discontinue development of MT-3724, MTEM’s only first-generation ETB. MTEM will focus on the clinical development of next-generation ETBs MT-5111, TAK-169, and MT-6402, as well as advancing next-generation preclinical ETB candidates against targets including CTLA-4, CD20, SLAMF-7 and CD45.

Takeda has communicated that its decision to turn over full rights of TAK-169, a second-generation ETB targeting CD38, was the result of Takeda’s ongoing portfolio prioritization. MTEM believes that TAK-169 is a potent molecule with a novel mechanism of action in multiple myeloma. It has demonstrated a favorable safety and efficacy profile in in vivo models and potency against daratumumab refractory patient samples. TAK-169 is in an ongoing Phase 1 study with dose escalation planned through six dose cohorts, in which the first patient was dosed in February 2020. To date, Takeda has enrolled and treated four subjects in the Phase 1 study. There have been no life-threatening toxicities, and no signs of capillary leak syndrome (CLS). The maximum tolerated dose (MTD) has not been reached, patient screening continues, and dose escalation is ongoing. One dose limiting toxicity (grade 2 myocarditis) was assessed in one subject. A mild elevation in Troponin I was noted in this subject after the third dose of TAK-169. No EKG or echocardiographic abnormalities and no clinical symptoms were noted. A stable elevation in high-sensitivity troponin was seen although no comparison to baseline was available as baseline levels were not required per protocol at the time. An independent radiologist and cardiologist reviewed the imaging in the case and concluded that there was weak to intermediate evidence of myocarditis. The subject had multiple pre-existing cardiac risk factors. No other cardiac adverse events were observed in any other subject. Pharmacokinetic and pharmacodynamic data of this first cohort have been in-line with predicted outcomes. MTEM looks forward to accelerating the full enrollment and completion of this safety and dose-finding study. MTEM’s manufacturing of TAK-169 has been qualified by Takeda and MTEM has sufficient TAK-169 drug supply to continue the Phase 1 study as planned. MTEM’s assumption of the full rights to TAK-169 is expected to result in cost savings in 2021 and MTEM’s guidance of cash runway into 2H23 is unchanged. Upon transfer of the full TAK-169 rights to MTEM, per the terms of the collaboration agreement, MTEM will owe Takeda low-single digit royalties on future net sales of TAK-169. MTEM anticipates that the transition of TAK-169 development from Takeda to MTEM will be conducted over the next 90 days.

In conjunction with taking on full development of TAK-169, MTEM has decided to discontinue development of MT-3724 to focus its resources on the development of next-generation ETBs. As previously disclosed, MT-3724 was placed on partial clinical hold by the U.S. Food and Drug Administration (FDA) following a treatment-related fatality in one subject who experienced Grade 5 CLS in the Phase 2 MT-3724 monotherapy study. Markedly high pharmacokinetic assay readings were observed in this and other subjects treated with a specific lot of MT-3724 material. Apart from this one subject, no life-threatening CLS events have been observed in any subject treated with MT-3724 at any dose tested and no instances of CLS of Grade 2 or higher have been observed with monotherapy treatment at doses of 50 mcg/kg or lower from any other lot of MT-3724 material. The FDA placed MT-3724 on a full clinical hold in late March and requested additional information and the development of a new quantitative assay specific to MT-3724, which would take significant time and investment away from MTEM’s priorities. At such time, MTEM had already discontinued dosing in all MT-3724 studies, as previously disclosed. Based on the foregoing, MTEM has now decided to discontinue development of MT-3724 to focus its resources on the development of next-generation ETBs.

There are no changes to the trials or plans for any other ETB product candidates, including MT-5111, TAK-169, and MT-6402, all of which utilize a next-generation ETB scaffold that has been designed to reduce or eliminate the propensity for innate immunity, including CLS. Furthermore, all MTEM ETBs other than MT-3724 are designed and manufactured to create a more homogeneous product that avoids the production of multiple species including protein aggregate species.

“We thank Takeda for co-discovering TAK-169 and all their efforts on developing the molecule. Takeda’s decision to reprioritize its pipeline allows MTEM to assume full rights to this promising program and we plan to take immediate steps to accelerate new site activation and patient enrollment in the TAK-169 study to generate data this year. While we are disappointed to discontinue development of MT-3724 after demonstrating forced internalization and having seen promising single agent responses in heavily pretreated DLBCL patients, the program provided important clinical proof of concept for our ETB platform and sets the stage for success with our next-generation ETBs,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “Our next-generation ETBs including MT-5111, TAK-169, and MT-6402, all benefit from improvements over the first-generation ETB technology, including increased potency, a de-immunized Shiga-like Toxin A (SLT-A) scaffold, and simpler design and manufacturing resulting in a more homogeneous drug product. We look forward to making continued progress in 2021 with the Phase 1 studies of MT-5111, TAK-169, and MT-6402 and to advancing our earlier stage pipeline of next-generation ETBs against a variety of other targets.”

About TAK-169

TAK-169 is an ETB consisting of a single chain variable fragment (scFv) with affinity for CD38, fused to the enzymatically active de-immunized SLT-A. TAK-169 is designed to bind and kill CD38 expressing cells in a manner consistent with SLT-A mediated cellular cytotoxicity. TAK-169 has been specifically designed to avoid competition with and to overcome the primary mechanisms of tumor resistance to daratumumab, the first approved monoclonal antibody targeting CD38. In preclinical investigation TAK-169 has been shown to be active in the presence of daratumumab. As such, TAK-169 may have the potential to be combined with approved CD38 targeted therapies. TAK-169 mediated ribosomal inhibition and cell death take place intracellularly so changes in the tumor microenvironment, such as CD55/59 upregulation, which inhibit immune-mediated mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) are not expected to inhibit TAK-169 activity.

About Molecular Templates

Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of SLT-A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates, including the anticipated benefits of Molecular Templates’ next-generation ETBs compared to its first-generation ETBs, such as MT-3724; statements relating to the development of MT-5111, TAK-169, and MT-6402; the expected budgetary impact of Molecular Templates’ assumption of the full rights to TAK-169; the expected timing of submitting various IND applications and conducting studies and generating data;
the expected participation and presentation at upcoming conferences; the anticipated effects of the COVID-19 pandemic on Molecular Templates’ ongoing clinical studies, manufacturing and preclinical development; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether Molecular Templates’ cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contact:

Adam Cutler
Chief Financial Officer
[email protected] 
862-204-4006         

MIAMI, FL, April 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to announce that the Company has surpassed $1 million in revenues directly driven by its COVID-19 testing program.

“We are truly grateful for the opportunity to be a part of the solution and help our community confront what promises to be a long-term battle with the virus, an elusive and formidable adversary,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care.

During 2020, the Company conducted over 4,700 COVID-19 tests that resulted in $599k in revenues. For the three months ended March 31, 2020, the revenue run rate associated with COVID-19 testing has accelerated, with approximately 2,900 tests, resulting in over $400k in revenues related to testing.

Mr. Weisberg continued, “We have recently added more testing equipment and analyzers and we hold a market-leading position in rapid results PCR and antigen-based testing systems. We are looking forward to continuing to expand our market share in COVID-19 testing throughout Florida State.”

For more information about Progressive Care, please visit the company’s website. Connect and stay in touch with us on social media:

Progressive Care Inc.
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS

PharmCoRx
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx

ClearMetrX
https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/

About Progressive Care: Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

Cautionary Disclosure Regarding Forward-Looking Statements Forward-Looking Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:
Carlos Rangel
[email protected]

THE WOODLANDS, Texas, April 05, 2021 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today that it will release its first quarter 2021 operating results on Wednesday, April 28, 2021, after the market closes. The Company has scheduled a conference call for Thursday, April 29, 2021, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss the results.

The call will be available by live webcast on ChampionX’s website at https://investors.championx.com or by dialing in as follows:

Please register for the webcast or dial into the call approximately 15 minutes prior to the scheduled start time.

A replay of the conference call will be available for approximately 30 days on ChampionX’s website or at ChampionXFirstQuarter2021CallReplay. Enter passcode 50141845.

About ChampionX

ChampionX (formerly known as Apergy Corporation) is a global leader in chemistry solutions and highly engineered equipment and technologies that help companies drill for and produce oil and gas safely and efficiently around the world. ChampionX’s products provide efficient functioning throughout the lifecycle of a well with a focus on the production phase of wells. To learn more about ChampionX, visit our website at www.championX.com.

Investor Contact:
Byron Pope – [email protected] – 281-602-0094

Media Contact:
John Breed – [email protected] – 281-403-3751

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.

As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host “Next Generation Care for Kidney Transplant Patients,” a 30-minute exhibitor showcase on April 6th from 11:00-11:30 a.m. Eastern Time.

Program details:

• Innovations in Kidney Transplant Care, with Dr. Christopher Boshkos, Medical Director of Kidney Transplantation at CareDx

• AlloSure: Standard of Care for Kidney Transplant Surveillance, with Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine

“I’m looking forward to highlighting research from the RADAR study, where AlloSure differentiates ambiguous allograft rejection in borderline cases, and presenting select case studies to illustrate long-term patient follow up with AlloSure from the KOAR registry,” said Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine.

In addition, CareDx is sponsoring the “Diagnosis of Acute Rejection in Kidney Transplantation: A Clinical Update,” a continuing medical education (CME) program on April 8th from 12:30–1:30 p.m. Eastern Time.

Program details:

• Acute Rejection in Kidney Transplantation: Pathophysiology and Impact on Outcomes, presented by Tarek Alhamad, MD, MS, Medical Director of Transplant Nephrology at Washington University School of Medicine in St. Louis

• Diagnostic Modalities for Acute Rejection in Kidney, presented by Deirdre Sawinski, MD, Assistant Medical Director, Penn Kidney Pancreas Transplant Program

• Advances in Non-Invasive Diagnosis of Acute Rejection in Kidney Transplantation, presented by Jonathan Bromberg, MD, PhD, Vice Chair for Research, University of Maryland School of Medicine

“The NKF Spring Clinical Meetings are always a highlight for us,” said Dr. Sham Dholakia, SVP Medical Affairs, CareDx. “We are excited to showcase the latest in kidney transplant surveillance data at this great event.”

Additional information is available at https://www.kidney.org/spring-clinical

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
[email protected]

Investor Relations
Greg Chodaczek
347-610-7010
[email protected]

Gig Harbor, Washington , April 05, 2021 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes®,” or the “Company”), (NASDAQ:HCDI), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced that it has entered into a purchase and sale agreement for the acquisition of approximately 1.85 acres of land in Tacoma, Washington for $2,000,000. The purchase is expected to close on or before May 22, 2021.

Located less than ten minutes to downtown Tacoma’s urban core job market, the 80 condominiums will cater to first-time home buyers searching for affordable options in the robust Tacoma area housing market. Harbor anticipates the 1 and 2 Bedroom units will be priced between $300,000 and $400,000 and fill a significant need in the local marketplace. Tacoma has been one of the strongest housing markets in the nation over the past two years and, in January 2021, as reported by Redfin, was the fastest selling market in the country. (Redfin puts Tacoma No. 1 for fastest selling housing market | Tacoma News Tribune (thenewstribune.com).)

Sterling Griffin, President and CEO of Harbor, stated, “Tacoma represents an ideal location for Harbor Custom Homes® to increase our Western Washington footprint and address the significant need for affordable housing in Tacoma. As home prices continue to escalate due to record low inventory levels, first-time homebuyers are often priced out of the market. We are directly addressing this fundamental gap in the marketplace and believe offering condominiums priced below $400,000 in Tacoma creates an excellent growth opportunity for the Company while providing a highly desirous product for first-time homebuyers.” 

About Harbor Custom Development, Inc.

Harbor Custom Development, Inc. is a real estate development company involved in all aspects of the land development cycle including land acquisition, entitlements, construction of project infrastructure, home building, marketing, sales, and management of various residential projects in Western Washington’s Puget Sound region; Sacramento, California; and Austin, Texas. Harbor has active or recently sold out residential communities in Gig Harbor, Bremerton, Silverdale, Bainbridge Island, and Allyn in the state of Washington. In addition, Harbor has acquired land and will begin constructing homes in two new markets beginning the second quarter of 202. Those markets are the Dark Horse Golf Course community 50 miles Northeast of Sacramento and established subdivisions approximately 22 miles from Austin, located in Driftwood and Dripping Springs, Texas.  Harbor Custom Development’s business strategy is to acquire and develop land strategically, based on an understanding of population growth patterns, entitlement restrictions, infrastructure development, and geo-economic forces.  Harbor focuses on real estate within target markets with convenient access to metropolitan areas that are generally characterized by diverse economic and employment bases and increasing populations.  For more information on Harbor Custom Development, Inc., please visit www.harborcustomdev.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.  Words such as “may,” “might,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.  These forward-looking statements are based upon current estimates and assumptions.  While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release.  These forward-looking statements are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission.  Thus, actual results could be materially different.  The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.